文献速递血液淋巴病理细胞病理与分子病理

淋巴结细针穿刺细胞学:诊断效能与拟议诊断分类的临床意义

Lymph node FNA cytology: Diagnostic performance and clinical implications of proposed diagnostic categories.
PubMed 文献 · Cancer Cytopathol · 2021-10-18

本研究评估349例疑似淋巴瘤的淋巴结细针穿刺细胞学(LN-FNAC)诊断效能及Sydney系统诊断分类的恶性风险。结果显示各分类恶性风险从不足标本的58.3%到恶性的99.3%不等,LN-FNAC敏感度达96.3%、特异度91.91%、准确率87.35%。标本质量佳及科内会诊可降低诊断错误率。

要点

  • LN-FNAC对淋巴瘤诊断准确可靠,敏感度达96.3%、准确率87.35%。
  • 不足标本恶性风险达58.3%,应重新取样以排除淋巴瘤。
  • 良好标本质量与科内多病理医师复核可降低诊断错误率。

核心结论

  • LN-FNAC对淋巴瘤诊断准确可靠,不足标本因恶性风险显著应重新取样。
  • 良好标本质量和多病理医师复核可提高LN-FNAC诊断效能。
  • 理解各诊断分类的恶性风险有助于指导患者管理。

研究设计与样本

  • 回顾性分析2018-2019年349例疑似淋巴瘤的LN-FNAC标本,含同期或非同期粗针活检。
  • LN-FNAC诊断与后续组织活检和/或临床评估的最终诊断比较。

主要发现

  • 患者平均年龄57.6岁,41%为女性;LN-FNAC作为初始诊断检查223例(63.9%),用于评估复发126例(36.1%)。
  • LN-FNAC诊断血液系统恶性肿瘤202例(57.9%)、非血液系统恶性肿瘤23例(6.6%)、反应性过程124例(35.5%)。
  • 后续组织活检42例(12%);各诊断分类恶性风险:不足58.3%、良性6.4%、非典型69.2%、可疑96.7%、恶性99.3%。
  • LN-FNAC敏感度达96.3%、特异度91.91%、准确率87.35%。
  • 无同期粗针活检的FNA病例中,最佳标本质量(P = .029)和科内会诊(P = .0002)降低诊断错误率。

关键数值与推荐

  • Sydney系统诊断分类恶性风险:不足58.3%、良性6.4%、非典型69.2%、可疑96.7%、恶性99.3%。
  • LN-FNAC诊断效能:敏感度96.3%、特异度91.91%、准确率87.35%。

临床怎么用

  • LN-FNAC可用于疑似淋巴瘤的诊断评估,结果可靠。
  • 不足标本应重新取样,因恶性风险达58.3%。
  • 应确保标本质量并推行科内多病理医师会诊以减少诊断错误。
  • 依据诊断分类的恶性风险分层指导患者后续管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite widespread clinical use, lymph node fine-needle aspiration cytology (LN-FNAC) lacks universal acceptance for definitively diagnosing lymphomas. This is likely due to reports of lower diagnostic performance, inconsistent terminology use in cytopathology diagnostic reports, and only limited data on the clinical implications of LN-FNAC diagnoses. Recently, a uniform LN-FNAC cytopathological diagnostic reporting system was proposed (the Sydney System). This study evaluated LN-FNAC diagnostic performance and risks of malignancy associated with the proposed diagnostic categories. METHODS: LN-FNAC specimens obtained in 2018-2019, with and without concurrent core biopsy, to evaluate for suspected lymphoma were analyzed (n = 349). LN-FNAC diagnoses were compared with final diagnoses obtained via subsequent tissue biopsy and/or clinical assessment. RESULTS: The mean patient age was 57.6 years, and 41% were female. LN-FNAC was the initial diagnostic test in 223 (63.9%), and it was used to evaluate for recurrence in 126 (36.1%). LN-FNAC diagnosed 202 hematological malignancies (57.9%), 23 nonhematological malignancies (6.6%), and 124 reactive processes (35.5%). Subsequent tissue biopsy was performed in 42 (12%). The risks of malignancy per diagnostic category were as follows: inadequate, 58.3%; benign, 6.4%; atypical, 69.2%; suspicious, 96.7%; and malignant, 99.3%. LN-FNAC demonstrated up to 96.3% sensitivity, 91.91% specificity, and 87.35% accuracy. Optimal specimen quality and the use of intradepartmental consultation reduced diagnostic error rates in FNA cases without concurrent core biopsy (P = .029 and P = .0002 respectively). CONCLUSIONS: LN-FNAC is accurate and reliable for the diagnosis of lymphoma. Inadequate LN-FNAC samples should be resampled due to a significant associated risk of lymphoma. The diagnostic performance of LN-FNAC may be improved with good specimen quality and reviews by multiple pathologists. Understanding the risks of malignancy associated with LN-FNAC diagnostic categories will help to guide optimal patient management.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Makarenko VV, DeLelys ME, Hasserjian RP, et al. Lymph node FNA cytology: Diagnostic performance and clinical implications of proposed diagnostic categories. Cancer Cytopathol. 2021. PMID: 34661975. doi:10.1002/cncy.22523

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。